ICYMI: new guidelines published in 2019 for CV prevention. It's important to assess CV risk in our patients because inflammatory diseases is now included as a risk factor (helps when deciding on starting pts on JAKi)- Dr. B Weber #RNL2024 @RheumNow https://t.co/nBQjs49avu https://t.co/apyDjaxudi

Primary ASCVD Prevention Guidelines for your reference from Dr. B. Weber. #RNL2024 @RheumNow https://t.co/erxIgeeLNU

Dr. B. Weber's review of the 2019 ASCVD risk factors which now includes inflammatory diseases (RA, HIV, PsO). She believes this will help us to better understand and grow our knowledge around patient risk. @RheumNow #RNL2024 https://t.co/9bV7VfExNf

Nuclear imaging assesses cardiac function, anatomy & microvascular dysfunction (MD). MD is underrecognized but can be measured by coronary flow reserve. MD is associated with worse longterm outcomes in systemic inflammatory disease – Dr. Weber #RNL2024 @rheumnow https://t.co/Bv22UKi6mM

Coronary Microvascular Dysfunction is associated with poor prognosis/outcomes in our systemic inflammatory disease patients. What is the gold standard for evaluating microvascular dysfunction? Coronary Flow Reserve (CRF) This is only one component to fully understand and assess… https://t.co/bMV5npkFwm https://t.co/ZYBXpQLPIF

Link between inflammation and cardiovascular disease, increased 1.5x in RA and 2-3 in PsA, treating inflammation is important to reduce CV risk, Brittany Weber #RNL2024 @RheumNow https://t.co/FCrOxa3drZ

Dr. B Weber gave a wonderful review of inflammation and cardiac risk in SLE, PsO/PsA, and RA. *SLE pts has a 50-fold increased risk of MI *RA pts are a 1.5x risk of CVD *PsO and PsA pts are also at increased risk for CVD #RNL2024 @RheumNow https://t.co/Hy4TmLzhzO

"The link between RA and CVD is the shared inflammatory pathways involving IL-1, IL-6 and TNF" -Dr. B Weber #RNL2024 @rheumnow https://t.co/aGPA8ZFNHj

CV disease risk is increased in patients with inflammatory rheumatic diseases. More data emerging in SLE, psoriasis, RA. – Dr. B Weber #RNL2024 @rheumnow https://t.co/wF9izGZug3

#RNL2024 @RheumNow Weber: Asymptomatic Lupus has higher rate of atherosclerosis at all age grps 35-44 yo F with SLE: 50X increased risk of MI compared to healthy pts in Framingham RA pts at 1.5x risk of CVD https://t.co/TJ5dLXwvNc

#RNL2024 @RheumNow Brittany Weber on Cardio-Rheumatology: "Everything has changed" on inflammation and CVD - Canakinumab 150 mg v PBO HR 0.85, p =0.02 - Colchicine v PBO HR 0.69, P<0.001 2023: FDA approval for colchicine as 1st anti-inflammatory for reducing CV events https://t.co/Tlv5Np2BHf

Check out some of the "newer" modalities available to us for evaluation of our rheumatology patients to better understand their cardiac risk. "Everything has changed in cardiac rheumatology." Dr. B. Weber #RNL2024 @RheumNow https://t.co/fki73W4Fk8